ChemVA: Interactive Visual Analysis of Chemical Compound Similarity in
  Virtual Screening by Sabando, María Virginia et al.
ChemVA: Interactive Visual Analysis of Chemical Compound
Similarity in Virtual Screening
Marı´a Virginia Sabando*, Pavol Ulbrich*, Matı´as Selzer, Jan Bysˇka,
Jan Micˇan, Ignacio Ponzoni, Axel J. Soto, Marı´a Luja´n Ganuza, Barbora Kozlı´kova´
A B C
D
Fig. 1: Overview of the ChemVA interface: a) Hexagonal view with an overview of a selected 2D projection, b) Detail view showing
all data items, which are colored according to a selected feature, c) 3D view enabling the user to observe the structural similarities of
selected compounds, d) Table view listing other important features of the compounds. All views are interactively linked.
Abstract— In the modern drug discovery process, medicinal chemists deal with the complexity of analysis of large ensembles of
candidate molecules. Computational tools, such as dimensionality reduction (DR) and classification, are commonly used to efficiently
process the multidimensional space of features. These underlying calculations often hinder interpretability of results and prevent
experts from assessing the impact of individual molecular features on the resulting representations. To provide a solution for scrutinizing
such complex data, we introduce ChemVA, an interactive application for the visual exploration of large molecular ensembles and their
features. Our tool consists of multiple coordinated views: Hexagonal view, Detail view, 3D view, Table view, and a newly proposed
Difference view designed for the comparison of DR projections. These views display DR projections combined with biological activity,
selected molecular features, and confidence scores for each of these projections. This conjunction of views allows the user to drill
down through the dataset and to efficiently select candidate compounds. Our approach was evaluated on two case studies of finding
structurally similar ligands with similar binding affinity to a target protein, as well as on an external qualitative evaluation. The results
suggest that our system allows effective visual inspection and comparison of different high-dimensional molecular representations.
Furthermore, ChemVA assists in the identification of candidate compounds while providing information on the certainty behind different
molecular representations.
Index Terms—Virtual screening, visual analysis, dimensionality reduction, coordinated views, cheminformatics.
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Small organic chemical compounds are the cornerstone of drug de-
sign. New medications are found by exploring a large number of
candidate compounds or by designing new ones. In the last decades,
high-throughput screening has been the main procedure applied during
the early stages of the drug discovery process [19, 41]. This process
requires chemical synthesis, experimental testing of large libraries of
compounds against a biological target (protein), and it has a high attri-
tion rate, which makes the process costly and time-consuming. These
drawbacks stimulated the development of virtual screening methods,
which consist of computational techniques for identifying compounds
binding to a drug target. Virtual screening allows to significantly nar-
row down the number of drug candidate compounds at a faster pace
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while lowering costs [39, 90]. These reasons make virtual screening an
essential part of the early-stage drug discovery process.
Computational techniques involved in virtual screening enable to
simulate and test the fitness of the candidate compound towards the
desired function without the need for chemical synthesis and expensive
wet laboratory work [71]. They typically consist of a high-dimensional
vector-based abstraction of a given molecule, which involves dealing
with the challenges inherent in high-dimensional data [27]. Many vi-
sualization tools for virtual screening have been proposed in the past
years to help medicinal chemists deal with the complex computational
methods. Such tools have been focused on providing proper means to
explore the chemical space and to enhance the interpretability of results
so that trusted and explainable decisions can be made [20, 55]. A com-
mon strategy followed by such tools is the application of dimensionality
reduction (DR) techniques [16, 55], which allow mapping compounds
from a high-dimensional chemical space into a lower-dimensional (of-
ten 2D or 3D) representation [16]. However, visual exploration of the
chemical space in the context of virtual screening entails a series of
new challenges, not yet addressed by the existing tools.
One of these important yet unsolved challenges is to study compound
similarity under the premise that similar molecules tend to have similar
bioactivity profiles [26]. Visualization tools should enable the domain
expert to interact with different sources of molecular information, and
provide complementary views that help find similarity determinants.
Most existing tools rely on a single mapping based on an arbitrarily
chosen set of molecular features. A visualization tool for virtual screen-
ing should also provide views and interactions that allow the domain
expert to assess the relationship between the bioactivity profiles of the
analyzed compounds and their spatial organization in the projected low-
dimensional space. Lastly, as a consequence of DR, pairwise distances
between compounds in the low-dimensional mapping can differ from
the corresponding pairwise distances in the high-dimensional space.
Information about the trustworthiness of these mappings should be visu-
ally presented to the domain expert in an interpretable way. Despite its
importance, most of the existing tools do not display this information.
These issues were the main driving force behind our research and,
as a result, we introduce ChemVA, an interactive system for the vi-
sual exploration of chemical compounds, targeted for virtual screening.
ChemVA provides domain experts with several linked views. One
set of views, consisting of 2D plots, supports the visual inspection
of multiple molecular representations after undergoing DR. Each DR
method produces a projection that can be displayed and mutually com-
pared using our newly proposed Difference view. Our tool handles the
overplotting problem of such projections, which is common for large
datasets. ChemVA also incorporates a correlation encoding to the plots,
which conveys the trustworthiness of a low-dimensional projection
based on the distortion with regard to the pairwise distances in the orig-
inal space. The plots are complemented by an interactive Table view,
which allows for sorting and filtering and shows detailed information
about the compounds being displayed, focusing primarily on features
related to drug-likeness. The tool also contains a 3D view that allows to
explore the structural similarity among selected compounds. This view
performs an alignment of selected compounds with respect to their
maximum common substructure, which serves to identify commonali-
ties and differences among them. Finally, ChemVA allows loading new
compounds to an existing dataset, which enables to study potential new
drug candidates in the context of the dataset under study. The main
contributions of this paper can be summarized as follows:
• A novel visualization tool for virtual screening that allows to com-
pare and contrast multiple dimensionality reduction projections
conveying complementary sources of molecular information.
• An approach for visually assessing the trustworthiness of each DR
projection, which enables the user to focus on the most suitable
vector-based molecular representations.
• A newly proposed Difference view that enables the comparison of
multiple DR projections and assessment of their trustworthiness
in terms of neighborhood preservation.
• Support for de novo drug design by means of a set of coordinated
views that allows to analyze newly designed compounds and
compare them with an existing set of chemical compounds.
• Functional validation of the proposed tool by means of two case
studies and a qualitative testing of the proposed views. These
evaluation activities were conducted by three domain experts and
one visualization expert.
2 RELATED WORK
In this section, we conduct a brief survey of existing approaches in
the different areas related to our work. We review DR techniques
and their application to the visualization of high-dimensional spaces,
focusing mainly on parametric DR methods. Then, we discuss the
state-of-the-art molecular visualization and visual exploration tools for
large molecular ensembles.
2.1 Visual Exploration of Multidimensional Data
Over the last few decades, a variety of visualization methods for multi-
dimensional data have been proposed [5, 40, 82]. Discovering patterns
in multidimensional data using a combination of visual and machine
learning techniques represents a well-known challenge in visual analyt-
ics. Visual exploration of multidimensional data allows for the injection
of unique human perceptual and cognitive abilities directly into the
process of discovering multidimensional patterns [32]. The challenge
mostly lies in having a large number of variables and their relationships
that have to be considered simultaneously. As the number of variables
increases, the user’s ability to understand interactions and correlations
between them is severely limited [80].
In this context, a variety of approaches have been introduced to
visually convey high-dimensional data by using two-dimensional pro-
jections, so that salient structures or patterns can be perceived while
exploring the projected data [45, 61, 91]. Therefore, one typical ap-
proach is to transform the original dataset using a DR technique, and
then to visually encode only the reduced data [50, 65]. A frequently
used visual encoding technique for showing the projected low dimen-
sional data is a scatter plot. Sedlmair et al. [66] carried out an extensive
investigation on the effectiveness of visual encoding choices, including
2D scatter plots, interactive 3D scatter plots, and scatter plot matri-
ces. Their findings suggest that the 2D scatter plot is the most suitable
approach to explore the output of different DR algorithms.
Many DR techniques have been proposed throughout the last decades
to transform multidimensional feature spaces onto a low-dimensional
manifold—typically onto a two or three-dimensional space—while
trying to preserve neighborhood relationships among the original data
instances [78, 86]. Among these methods, t-distributed Stochastic
Neighbor Embedding (t-SNE) [77] has been widely adopted, specifi-
cally for the visualization of very high-dimensional data [43,57,70,85].
Many of the proposed DR techniques are non-parametric, i.e., they
find patterns in specific manifolds and do not provide means to map
new data points from the original high-dimensional space to the la-
tent space. Therefore, their out-of-sample extension is not possible.
Linear methods for DR, such as PCA [84], LDA [12], or MSR [69],
have been extensively used, but are constrained to linear transforma-
tions of the original data. In contrast to other non-linear techniques,
e.g., SOMs [31], MDS [9] or autoencoders [34], which allow to map
non-linear data, t-SNE tackles the crowding problem effectively by
using a heavy-tailed distribution for arranging data points in the low
dimensional space [77]. Practically speaking, addressing the crowd-
ing problem yields better-looking visualizations. Although t-SNE is
non-parametric, there is a parametric t-SNE version [76], which seeks
to overcome this limitation. Nonetheless, it is often difficult to find
an optimal configuration of hyperparameters for these models, which
in turn yields noisy projections compared to those obtained using the
non-parametric version of the algorithm [44, 87, 93].
In particular, visualization tools for virtual screening should allow
medicinal chemists to analyze how a previously unseen compound
interacts with or relates to other known compounds. For this reason,
DR techniques used in the visualization tools for virtual screening
should provide means for mapping unseen compounds and they should
be fast enough to enable interactive use.
2.2 Visualization of Molecular Structures
Molecular visualization is one of the oldest branches of visualization
as it has a well-established basis of visual representations, which has
been largely embraced by biochemists and biologists. These—mostly
3D—representations are integrated into many available molecular vi-
sualization tools, such as PyMOL [64], VMD [21], Chimera [54], or
YASARA [35]. Besides these tools, there are also several others—
mainly web-based ones—that can be embedded into other applications;
for instance, Jmol [25], JSmol [17], or 3Dmol.js [58]. However, none
of these tools is directly applicable to the problem of visual exploration
of large ensembles of molecular structures and the similarities in their
structure and properties. A more extensive overview of the currently
available approaches to molecular visualization and molecular systems
can be found in the survey by Kozlı´kova´ et al. [33].
Visual inspection of small molecules is supported in different ways
by some available tools. Smaller molecules are commonly visualized
in 2D in order to better depict their structure, such as in LigPlot+ [37].
This tool serves mainly for exploring the interactions between a ligand
and its target protein, by projecting its molecular structure and the
protein amino acids onto the 2D plane. However, such a tool is not
applicable to the task of analyzing multiple molecular compounds.
The exploration of large sets of chemical compounds constitutes an
ideal task from the visual analytics viewpoint, and several such tools
have already been proposed. The closest to our proposed tool is CheS-
Mapper [16]. It enables to load data from several chemical databases,
to calculate molecular descriptors, to observe clusters of compounds
in a reduced 2D space, and to display the 3D representation of the
compounds. Nonetheless, the tool does not provide an option to inter-
actively compare different projections and does not support inspecting
the physical-chemical properties of a newly added compound.
A similar tool is Data Warrior [62], which consists of several basic
visualization methods and specialized views to show an overview of
the whole chemical and pharmacophore space of the input dataset.
However, the tool is not designed for specific tasks related to the early-
stage drug discovery process that is addressed in our tool. More recently,
Yoshimori et al. [89] proposed a technique for visually summarizing
information about multiple Structure-Activity Relationship Matrices,
based on molecular grid maps and 3D activity landscapes. Nevertheless,
due to its specificity, it cannot be extended to operate with additional
physical-chemical properties and descriptors.
Janssen et al. [24] introduced a method that uses a visual mapping
based on t-SNE projections for finding new potential kinase inhibitors.
The views provided by the tool show the results of clustering and a tree-
like structure of compounds. However, such views are not designed to
easily extract information about the structural similarity of compounds.
A similar concept was introduced by Probst and Reymond [56]. Their
approach is tailored to process very large high-dimensional datasets and
the compound similarity is expressed by the proximity of compounds
through tree branches.
Naveja and Medina-Franco [49] introduced the constellation graphs
of chemical compounds clustered according to a shared core scaffold
in the 2D projections of their geometry. Each cluster is annotated with
a small view containing the projected core. While such constellation
graphs provide an innovative approach for the visualization of com-
pounds, they do not fit our requirements for visual exploration in the
context of virtual screening. Synergy Maps [38] is another web-based
application for displaying relationships between compounds and under-
standing potential synergies between them. The tool shows pairwise
combinations of properties of compounds using a network representa-
tion. Nonetheless, the node-link diagrams do not scale properly, which
hinders its application for large ensembles of compounds.
Although methods for assessing the trustworthiness of DR tech-
niques have been proposed [2, 10, 53], to the best of our knowledge
none of the existing approaches for visualization of molecular struc-
tures allows to perform this task. Moreover, they do not provide means
to compare the results of multiple projections.
3 BACKGROUND
In this section, we provide details on the theoretical background of our
proposed tool, which includes the molecular representations used and
their semantics, as well as a short description of the chemical features
of major relevance for drug-likeness.
3.1 Vector-Based Molecular Representations
Research in cheminformatics suggests that there are several different
factors involved in assessing chemical compound similarity, which go
beyond having similar geometric arrangements of atoms and bonds [3,
42]. Given the relevance of assessing compound similarity in virtual
screening, it is important to provide medicinal chemists with a variety
of vector-based molecular representations that capture different aspects
of the compounds under study and that are complementary to each
other. In this sense, ChemVA provides four different sources of data:
• Extended Connectivity Fingerprints (ECFPs) [59] encode the
topological information of the molecular structure as a fixed-
length vector of bits.
• Daylight Fingerprints [11] are path-based vectors of bits that en-
code all fragments of a molecule, which are obtained by traversing
its molecular graph.
• Molecular Descriptors [74] are numerical values associated with
the chemical constitution of a molecule. They convey information
such as molecular weight, electronic configuration, solubility, etc.
• Molecular Embeddings [23] are a rather novel type of vector-
based representations. They are typically obtained by applying
machine learning models that are trained to learn data representa-
tions of molecules from large and diverse sets of compounds.
We selected these four vector-based molecular representations as our
sources of data because they capture different information about the
compounds, thus allowing for a broader analysis of the data under study,
and because each of them is considered to be the state-of-the-art of their
type. While we are utilizing these four vector-based molecular repre-
sentations, it is worth noting that ChemVA remains independent from
the chosen sources of data. Details of their calculation are provided in
the Supplementary Material.
3.2 Molecular Features Related to Drug-Likeness
Some molecular features are of major interest to drug designers and
medicinal chemists in the context of virtual screening. In particular,
molecular features related to drug-likeness allow scrutinizing the com-
pounds in terms of their viability as potential new drugs. ChemVA
takes into consideration a subset of such features:
• Molecular weight represents the average mass of the molecule
expressed in Daltons (Da). Drug-like compounds are expected to
weigh from 160 to 500 Da.
• logP is a quantitative measure of lipophilicity, and indicates how
easily a substance is absorbed by living tissue. Drug-like com-
pounds often exhibit logP values from −0.4 to +5.6.
• Acidic Dissociation Constant and Basic Dissociation Constant
are quantitative measures of the strength of an acid (or base) in a
chemical solution. They are good indicators for a drug’s ability to
enter the bloodstream and to accumulate in tissues or secretions.
• Lipinski’s Rule of 5 (RO5) is a rule of thumb to determine whether
a compound is likely to be active in humans. This rule states that
an orally active drug violates no more than one of four criteria
based on threshold values of specific chemical features.
• Weighed Quantitative Estimate of Drug-likeness (QED) is a score
computed based on chemical features linked to drug-likeness, and
it ranges from 0 (non drug-like) to 1 (drug-like).
4 REQUIREMENTS
Over the course of one year, we conducted numerous sessions with the
group of protein engineers from the Loschmidt Laboratories at Masaryk
University. Based on their input, we identified several limitations of the
existing approaches for virtual screening and summarized them into a
list of requirements. The experts agreed that these requirements cover
the most critical aspects of a virtual screening workflow. One of the
experts, who is also the co-author of this paper, has dedicated signifi-
cant time ensuring that our implementation addresses the requirements
by iteratively checking and commenting on the progress. His 4-year
research experience in protein engineering, along with his internal con-
sultations with the head of his group, provided the necessary domain
knowledge for the design of the tool.
R1: Overview and detailed analysis of a molecular ensemble in the
low-dimensional space. For large datasets, scatter plots, which are
commonly used to represent the DR output, may suffer from occlusion
problems for large datasets. Therefore, the tool should provide visual
support for the analysis of data on different levels of abstraction, from
the overall distribution of the compounds within the 2D space to the
detailed view of individual compounds for a selected region of interest.
R2: Visual inspection of multiple projections. A set of compounds
can be expressed by different vector-based molecular representations,
each yielding a different DR projection. The tool should enable the user
to intuitively combine information encoded in the individual projections
to allow studying at once the similarity between compounds based on
different molecular representations. More specifically, this includes
exploring similarities and differences between chemical compounds,
expressed by the different projections. Additionally, the visual repre-
sentations and interactions should help the domain experts evaluate the
suitability of the selected DR model.
R3: Evaluation of the trustworthiness of projections. Users need
proper visual support for assessing the trustworthiness of a low-
dimensional projection based on the distortion with regard to pairwise
distances between compounds in the original space. When such trust-
worthiness can be compared on different DR projections, users can
focus the exploration on a subset of molecular representations.
R4: Comparison of compounds according to features related to
drug-likeness. Chemical compounds have many features and descrip-
tors related to drug-likeness that can complement other molecular rep-
resentations in the task of virtual screening. Therefore, it is desirable
to provide users with an option to visualize these additional features
along with the projections.
R5: Comprehensible viewing of 3D structural similarity. The tool
should support the inspection of individual compounds in terms of their
3D geometry, as well as the visual comparison of common 3D substruc-
tures in a selected set of compounds. For multiple compounds, such a
view should convey the information about similarities and differences
in their 3D structure.
R6: Possibility to add new compounds and comparison with the
existing data. The tool should support the process of exploration of
different features and bioactivity for newly added compounds. The new
compound should be projected using the DR model and integrated into
the remaining views, so that the user can compare its features to those
of the compounds in the existing dataset.
5 CHEMVA DESIGN AND IMPLEMENTATION
The design process of ChemVA followed the requirements listed in Sec-
tion 4. These requirements are addressed through several coordinated
views, which pose challenges to the layout of the tool. ChemVA was
developed in JavaScript using D3.js v5 [6] and a Node.js server [73]
built using the Express framework and REST API for the connection to
supporting services. We used Unity3d [72] ported to WebGL [29] for
the development of 3D components. Two back-end web services, used
for computing the alignment of 3D structures and for computing the 2D
coordinates of newly added compounds, were developed using Flask
web framework [60] and written in Python v3. Excluding one of the
views [13], all of the functionality was designed and written in-house,
prioritizing the system responsiveness and real-time experience with
interactions.
In this section, we first describe the individual views supported by
ChemVA in detail, then we briefly introduce the DR model applied in
our tool, and lastly we present the main functionality supporting the
analysis of newly added compounds.
5.1 ChemVA Views
The initial layout, depicted in Figure 1, contains the Hexagonal view,
Detail view, and 3D view (Figure 1 A, B, and C, respectively) in the
top row of the canvas, whereas the bottom row contains the Table view
(Figure 1 D). These views account for requirements R1, R4 and R5. For
tasks involving the comparison of projections, stated in requirement R2,
additional views need to be displayed. After careful consideration, we
decided to position these views between the two rows of the basic layout
(see Figure 8), as they need to be as close as possible to the default 2D
plot views. This row can be shown or collapsed on demand and allows
the user to choose which views should be included (e.g., Hexagonal,
Detail, or Difference views). The purpose of this layout is to allow
the user to observe the data from different perspectives. In particular,
the Difference view shows the differences between the compound
neighborhoods from one projection into another, thus allowing the
user to compare different projections. The tool uses the color scheme
proposed by Okabe & Ito [22], so it is accessible to users with color
vision deficiency.
5.1.1 2D Plot Views
The core of ChemVA consists of 2D plots, which give the user an
overview of the distribution of compounds in a selected DR projection
using a given molecular representation. This overview is supported by
the Hexagonal view, a well-adopted and commonly used approach to
visualize the outcome of DR techniques [66]. The Hexagonal view
aims to overcome the overplotting problem, in which the projected data
items overlap and cause visual clutter , thus limiting the interpretability,
especially for datasets evincing high similarity between data items.
The Hexagonal view of ChemVA seeks to solve this problem by
aggregating individual data items into individual hexagons. The user
can interactively select a subset of hexagons of interest and explore
the distribution of individual data items within the Detail view. The
combination of the Hexagonal view and the Detail view aims to fulfill
requirement R1. Finally, since ChemVA is tailored to support the
visual comparison of different projections, it also offers the Difference
view. This view was specifically designed to address that task, which is
stated in requirements R2 and R3.
Hexagonal View
The Hexagonal view (Figure 2) provides the users with an overview
of one particular 2D projection of the dataset. In order to avoid over-
plotting when dealing with large datasets, the chemical compounds are
aggregated into hexagonal bins. We opted for the hexagonal binning
approach, first described by Carr et al. [7], as it evidences signifi-
cant advantages for efficient data aggregation in comparison to other
approaches. This is related to the low perimeter-to-area ratio of the
hexagonal shape, which reduces the sampling bias. The ideal shape for
that is a circle but it cannot be used for the full-coverage division of
the plane. Hexagons are the most circular-shaped objects, enabling to
construct such a division in an efficient way.
The Hexagonal view can be applied to any of the vector-based
molecular representations described in Section 3.1. Each hexagon has
an assigned opacity, which corresponds to the number of compounds
aggregated within the hexagon. A higher opacity corresponds to a larger
number of compounds inside the hexagon. In this way, the Hexagonal
view depicts the distribution of the compounds yielded by the DR,
so users can recognize areas with a high density of compounds. The
color of a hexagon encodes the prevailing trend among its compounds
for a selected feature, which is by default their bioactivity but can be
switched to other molecular properties, including the trustworthiness
of the projection (requirement R3).
Fig. 2: The Hexagonal view shows the density of the distribution of
compounds in the 2D projection, which is encoded using into opac-
ity, and the prevalence of the bioactivity of the compounds, which is
encoded using color. The size of the hexagons can be adjusted.
The granularity of the Hexagonal view can be changed using a
slider, which enables a more detailed view of the distribution of
the compounds. In order to preserve the readability through the
range of different granularity levels, the opacity is enhanced linearly
with respect to the decrease of the hexagon size. Additionally, the
Hexagonal view enables the user to select several hexagons at once.
The compounds within the selected hexagons are then filtered through
the other linked views (Detail view, 3D view, and Table view), where
they can be explored in more detail.
Detail View
Upon selecting a subset of compounds in the Hexagonal view, the
user can explore the selected data in the Detail view, depicted in Fig-
ure 3. In this view, the compounds are represented using a standard
scatter plot, enhanced by a subtle overlay of the same hexagonal grid
as in the Hexagonal view, which helps users keep the correspondence
between the zoom level in these views. This is important because the
Detail view displays only the selected hexagons zoomed in after the
selection. To further enhance the link between the Hexagonal and
Detail views, the corresponding hexagons are highlighted when the
user hovers over them in any of these views. In order to perform a
selection of individual compounds in this view, a lasso-shaped selector
is supported. The selected compounds are then displayed in the 3D
view and also highlighted in the Table view (Section 5.1.2).
As in the case of the Hexagonal view, the Detail view can be set to
any of the vector-based molecular representations described in Section
Fig. 3: The Detail view displays individual compounds as dots in a
selected projection (ECFP fingerprints in this case). The color can be
mapped into one of the features (activity towards Serotonin 1a receptor
in this case).
Fig. 4: The Difference view showing the decomposition of the local
neighborhoods from one projection to another one. Here, the refer-
ence projection A corresponds to ECFP fingerprints and its selected
hexagons are highlighted in gray. Projection B corresponds to Daylight
fingerprints (inner hexagons in black). The opacity of hexagons in A en-
codes the value of the metric used for the trustworthiness of projection
(see Section 6).
3.1. In addition, all properties and features described in Section 3
can be color-encoded on points representing each compound. These
features are selected from a drop-down menu, and their color encodings
are chosen according to their type, i.e., quantitative, such as molecular
weight, or categorical, such as bioactivity towards a target protein.
Another quantitative property that can be used for color encoding
corresponds to the correlation scores, which encode the trustworthiness
of the DR projection of the compound (requirement R3). These
scores were computed using Pearson and Kendall correlation, whose
calculation is explained in the Supplementary Material.
Difference View
In order to support the task of comparing the outputs of different 2D
projections, as stated in our requirement R2, we propose a novel view
called Difference view, that combines and contrasts two selected 2D
Hexagonal views, A and B. Initially it displays a hexagonal layout sim-
ilar to that presented in the Hexagonal view, where the opacity of each
hexagon encodes the computed correlation score of the trustworthiness
of the projections A and B under study (requirement R3).
The Difference view adopts the hexagonal layout from one of the
projections to be compared, which we denote as the reference projection.
When we choose projection A as the reference and perform a selection
operation in the Hexagonal view of A, we search for the positions
of the compounds falling into this selection in projection B. These
positions are encoded as inner smaller hexagons inscribed into the
original hexagonal grid of the Difference view, as depicted in Figure 4.
In other words, this view shows where the compounds from the selected
hexagons in projection A are located in projection B. The size of inner
hexagons corresponds to the number of compounds falling into the
same hexagonal bin.
The primary purpose of this graph is to help illustrate which regions
of the dataset preserve their neighborhoods from one vector-based
molecular representation to another one when undergoing a DR proce-
dure. In this way, the user can rapidly compare two different projections
and assess the trustworthiness of the neighborhoods generated by the
DR techniques. If the level of fragmentation from one projection to
another is high, i.e., a segregation of the content of one hexagon into
many small, fairly separated and scattered hexagons is observed, it
can be inferred that these molecules behave differently according to
the chosen molecular representation, thus they might be taken into
consideration cautiously and inspected in more detail.
Fig. 5: The Table view. Each row corresponds to one compound and its
selected features. The right side panel shows the statistical overview of
the distribution of values across the dataset.
5.1.2 Table View
Besides from the vector-based molecular representations used in the
DR projections and displayed in our 2D plot views, there are several
other molecular features related to drug-likeness that should be taken
into consideration when analyzing the compounds, as stated in require-
ment R4. ChemVA enables the users to explore such features, listed in
Section 3.2, by means of a Table view which offers advanced interac-
tion options. We adopted a well-established tool, published by Gratzl et
al. [15], and its extension [13]. As these tools perfectly fit to our needs,
we incorporate them to ChemVA. Further details about the broad range
of interaction possibilities can be found in the original papers.
In addition to the list of compounds, the Table view provides the
users with graphical elements in the form of juxtaposed bar charts and
box plots in the right side panel. By default, the compounds in the
table are logically grouped by their membership to hexagons in the
Hexagonal view. These groups can be either expanded or compressed.
When compressed, the table displays the box plots of the distribution
of the values for each feature in the hexagon, as shown in Figure 5.
This view is interactively linked with the other visual components
of ChemVA. When performing a selection in the 2D plot views, the
corresponding compounds are automatically highlighted in the Table
view. Conversely, when the user selects compounds in the Table view,
the corresponding compounds are highlighted in the Detail view, dis-
played in the 3D view, and the corresponding hexagons are highlighted
in the Hexagonal view.
5.1.3 3D View
The geometric similarity between selected compounds can be explored
using our 3D view. The visual representation of atoms and bonds, as
well as the coloring of the compounds, are based on standard repre-
sentations used in molecular chemistry, with specific colors reserved
for each chemical element. It also offers standard interactions, such as
panning, zooming, and rotation of the displayed structures.
Fig. 6: 3D view with 66 aligned molecules. Common atoms and bonds
are rendered more opaque than the less common components.
(a) (b)
Fig. 7: Reducing the visual clutter visible in Figure 6 by (a) filtering out
the non-common parts of compounds and by (b) changing the opacity
of the whole structure.
Compound similarity can be better perceived when the compounds
are structurally aligned in the view. To serve this purpose, we use a
structural alignment functionality provided by the OpenBabel tool [51].
Further details about this functionality are provided in the Supplemen-
tary Material. Once molecules are aligned, the user should be able
to easily identify their common parts, i.e., the subsets of atoms and
bonds that are present in most of the selected compounds, as stated
in requirement R5. In addition, we incorporate opacity modulation
with respect to the frequency of occurrence of atoms and bonds. In
other words, the opacity of atoms and bonds is calculated based on the
number of atoms of the same type that are aligned to the same spatial
position. As a consequence, common substructures are rendered more
opaque. An example of such alignment can be seen in Figure 6.
Depending on the number of selected compounds and their similari-
ties, the 3D visual representation can become fairly cluttered (Figure 6).
To reduce this visual clutter, the 3D view offers hiding and showing
hydrogen atoms and bonds on demand, changing the size of atoms and
bonds, as it can be seen in Figure 7(a), and also changing the opacity
of the whole structure. Figure 7(b) shows an example of using these
functionalities on a cluttered subset of compounds.
In some cases, the user wants to focus only on the common parts
of the structure. Therefore, we have also included functionality for
filtering out atoms and bonds. Figure 7(a) shows how the visibility
of the common substructure among 66 compounds is improved by
using this feature. Finally, as the user might also want to analyze the
non-common parts of the compounds, the 3D view provides an option
to invert the opacity, so that the common part of the structure becomes
more transparent than the rest.
5.2 Dimensionality Reduction
t-Distributed Stochastic Neighborhood Embedding (t-SNE) [77] is con-
sidered to be the state-of-the-art technique for dimensionality reduction,
particularly for visualizing very high dimensional data. t-SNE maps
neighboring data points to a lower-dimensional space, aiming to pre-
serve the neighborhood relationships (locality). It applies the Student’s
t-distribution on the low-dimensional space aiming to tackle the crowd-
ing problem, which happens when many points clump together in the
low-dimensional projection. These traits make t-SNE a suitable tool
for visually exploring molecular spaces, where local neighborhoods are
of utmost interest for analyzing compound similarity.
However, t-SNE has a major limitation, which is that it is a non-
parametric technique. After testing Parametric t-SNE [76] and con-
sistently failing to attain good quality projections, we developed our
own parametric dimensionality reduction model. This model was con-
structed based on a feed-forward neural network, which was trained to
learn the 2-dimensional coordinates of a previously computed t-SNE
projection of the data. We trained four of these parametric models
for each reference dataset used in ChemVA, one for each molecular
representation. The performance of our parametric models was eval-
uated by measuring the Pearson correlation coefficient between the
predicted coordinates and the actual coordinates, i.e., those obtained by
means of the t-SNE projection. We provide details on the parameteriza-
tion used for t-SNE and the parametric models in the Supplementary
Material. The t-SNE projections were computed using tools from Scikit-
Learn [52], whereas the parametric models were built using Keras and
Tensorflow [8].
5.3 Adding New Compounds
ChemVA provides an option to add new compounds to the dataset
being studied in order to explore their features and compare them
with those of other compounds. By means of this functionality, the
expert can assess the potential of this newly added compound prior to
extensive wet lab testing. The support for this important feature fulfills
requirement R6.
A new compound is loaded to ChemVA by specifying its SMILES
formula [83]. A back-end service of ChemVA calculates the molecular
features listed in Section 3.2. After computing such molecular represen-
tations and features, ChemVA uses the parametric models (described
in Section 5.2) to obtain the 2D coordinates of the compound in each
projection. Finally, the newly added compound is displayed in all the
supported views with yellow color to ease its identification. This color
encoding prevails throughout the views, as it can be seen in Figure 8.
6 EVALUATION AND CASE STUDIES
The evaluation of ChemVA consisted of two main stages. The first
stage was conducted by one domain expert involved in the functional
design of the tool (see Section 4), and consisted of two case studies.
The second stage was conducted by one visualization expert and two
domain experts, who were not involved at any point during the design
or development of ChemVA. This stage consisted of a session where
the different views where qualitatively evaluated and general feedback
about the usability and functionality of the tool was gathered afterwards.
6.1 First Stage - Case Studies
During the first stage of the evaluation, several additional functional
requirements for the tool itself were identified by the domain expert,
such as loading and storing selections, downloading the displayed
3D conformations, and highlighting the compounds in the Table view
after clicking on them in the 3D view. These additional functional
requirements were addressed in time for the case study evaluation.
ChemVA was tested on two case studies, which were built upon two
different datasets retrieved from ChEMBL [14]. The first dataset was
composed by merging ligands binding to the Serotonin 1a receptor1
and Dopamine D2 receptor2, whereas the second dataset comprised
ligands to the P-glycoprotein 13. We assigned a categorical label to
each compound according to its experimentally measured IC50 bioac-
tivity value towards the target(s) under study. Compounds showing
IC50 values below 10 nM were labeled as Active; compounds between
10 and 1000 nM were labeled as Moderately Active, and those over
1000 nM were labeled as Inactive. The serotonin-dopamine dataset
comprises 118 compounds, whereas the P-glycoprotein dataset contains
893 compounds.
6.1.1 Case Study 1: Analysis of Chemical Determinants of
Activity Towards Serotonin and Dopamine Receptors
This case study is based on the serotonin-dopamine dataset, a set of
compounds that have data about antagonistic activity against the sero-
tonin 5HT1A and dopamine D2 receptor. These receptors of neuro-
transmitters are targets of many psychoactive pharmaceuticals, i.e.,
antidepressants, antipsychotics, and anxiolytics. In the field of psy-
chopharmacology, small molecules with different activity towards sev-
eral receptors are used to alleviate side-effects [48, 67].
The goal of the study was to find chemical determinants of biological
activity towards serotonin and dopamine receptors. According to the
domain expert, similar compounds could be easily found in the Detail
view in all four projections, based on their proximity. After identifying
groups of potentially similar compounds, the domain expert searched
for groups of compounds that were active towards both receptors and
1https://www.ebi.ac.uk/chembl/target report card/CHEMBL214/
2https://www.ebi.ac.uk/chembl/target report card/CHEMBL217/
3https://www.ebi.ac.uk/chembl/target report card/CHEMBL4302/
that had desirable pharmacological properties, such as following the
Lipinski‘s RO5 and having a high QED score. This exploratory search
was done on the Hexagonal view, by adjusting the size of the hexagons
to match the observed groups of compounds in the different projections.
Afterwards, the domain expert used the Kendall and Pearson corre-
lation color encoding in order to observe whether the projections were
trustworthy, and thus the hexagons being considered would effectively
group similar compounds. A set of hexagons was preselected and the
Table view was used, in which the domain expert analyzed the distri-
butions of all drug-likeness features of the selected compounds using
the summary information displayed in the column headers. As a result,
the expert identified a hexagon that grouped active compounds towards
both receptors with desirable drug-likeness features.
The domain expert selected those compounds and performed an
alignment in the 3D view, finding that their structures were very similar.
These compounds were also contrasted to inactive compounds within
the same hexagon using the 3D view. This allowed the domain expert
to gain insight into the relevant substructures of a potential new drug
candidate. At this point, the domain expert highlighted how easy it was
to find and visualize the common 3D structure of a group of compounds.
Finally, the structures of active compounds towards both receptors
were downloaded from ChemVA. Five new compounds were created
and loaded to ChemVA, as shown in Figure 8. They were compared
to the downloaded structures using molecular docking. This process is
described in the Supplementary Material. The domain expert found out
that the new structures effectively bound to a known antagonist binding
pocket and three out of the five newly created structures showed slightly
better binding energies than structures from the dataset used for their
design, which were already highly active. This shows that ChemVA
could be effectively used for drug design purposes, leading to newly
designed compounds that have the desired qualities and bioactivity
profiles.
6.1.2 Case Study 2: Analysis of Structural Determinants of
P-glycoprotein Inhibitors
This case study was based on the P-glycoprotein dataset, consisting of
small molecules with inhibitory activity against human P-glycoprotein.
This protein is exclusively overexpressed in cells of many cancer types,
causing multidrug resistance of these cells and thus impacting on the
performance of chemotherapy treatments. It also affects the effec-
tivity of many drugs by altering their ADME-Tox properties. [68].
P-glycoprotein has proven to bind to many structurally dissimilar sub-
strates, thus an interesting use case for our tool was to find structural
determinants of a good P-glycoprotein inhibitor and to compare known
active ligands towards this target.
According to the domain expert, the P-glycoprotein dataset contains
a vast number of diverse compounds that interact with the target pro-
tein. The goal of this case study was to find chemical determinants of
compounds with a very high logP value, which are scarce in the dataset.
In order to achieve this goal, the domain expert used the Table view
to filter compounds with logP values higher than 6.75 and then sorted
them based on their logP value and their correlation scores, which
measure the trustworthiness of the molecular representation currently
being projected onto the 2D plot views.
The domain expert used the filtering options provided by the Ta-
ble view in order to find a set of compounds complying with all
the requested criteria, i.e., high logP value, activity towards the P-
glycoprotein and following Lipinski‘s RO5. Afterwards, chemically
similar compounds were selected from this subset and further analyzed
using the Hexagonal view. Hexagons containing active compounds
were selected and thoroughly explored using the Detail view, in which
logP was used for color encoding. Finally, the domain expert used the
3D view to find common substructures among the selected compounds
and successfully identified chemical determinants of bioactivity. This
was achieved by analyzing structural patterns related to lipophilicity,
indicated by high logP values. This workflow is depicted in Figure 9.
A B C
D E F
G
Fig. 8: The newly designed compounds were projected by ChemVA near the selected dataset compounds in the Daylight projection (top),
occupying the same hexagons, and slightly further from them in the ECFP Fingerprints projection (bottom). The Difference view on the bottom
right illustrates the redistribution of the selected regions. a) Hexagonal view, b-d-f) Detail view, c) 3D view, e) Difference view, g) Table view.
6.2 Second Stage - Qualitative Evaluation by External Ex-
perts
In the second stage we introduced ChemVA to two domain experts
from the Loschmidt Laboratories at Masaryk University who evaluated
our tool in terms of functionality and user-experience. We also intro-
duced our newly proposed Difference graph to one visualization expert
(see Acknowledgments), who has vast experience in DR techniques.
None of the experts were involved at any stage during the design and
development of ChemVA.
First, we conducted a brief introduction to the layout and the pro-
posed visualization methods. This stage took approximately thirty
minutes for each of the evaluations with the domain experts, after
which they were able to use the tool without any further assistance.
While both of the domain experts highlighted the intuitiveness of the
Hexagon and 3D views, they also pointed out the need for an appropri-
ate documentation describing other views, such as our novel Difference
view, in order to support usability. According to the domain experts,
ChemVA allows to easily compare numerous properties, which is an
uncommon but very useful feature in tools for virtual screening. Both
of the domain experts highlighted the usefulness of having different
projections, and the ability to focus on a specific source of data using
the correlation scores and comparing them by means of the Difference
view. According to the visualization expert, the Difference view does
a good job by enabling the user to visualize how the two mappings,
hence the two feature spaces, are correlated in terms of grouping the
same set of molecules together. Both domain experts enumerated sev-
eral examples from their own ongoing research activities which they
claimed could be enhanced by ChemVA, in terms of time and effort For
instance, a drug design task aimed at identifying on- and off-target drug
responses, or the analysis of 4300 FDA-approved drugs for usability
in the treatment of COVID-19, which is currently carried out using
cumbersome scripting and manual feature selection.
7 RESULTS AND DISCUSSION
In this section we summarize some final remarks and feedback provided
by the domain experts who conducted both stages of the evaluation
of ChemVA. We discuss the results of both case studies, as well as
strengths and limitations of our tool. As shown in Section 6.1, the
goals for both case studies were effectively fulfilled using ChemVA,
which suggests that the tool has the potential to be widely adopted and
used by medicinal chemists. This claim is also supported by the results
of the qualitative evaluation performed by external experts, described
in Section 6.2. Our tool allowed an intuitive comparison of sets of
chemically similar compounds. In contrast to other tools, which only
allow to sort and filter compounds by a set of properties, ChemVA en-
abled a comprehensive analysis of the data by taking into consideration
multiple molecular representations and levels of granularity. In the case
studies, this was aided by specific features of our tool, such as grouping
compounds in hexagons and allowing to adjust their size.
In the first case study, the Detail view assisted the domain expert
in distinguishing similar compounds based on proximity in all four
projections (R1 & R2). Furthermore, the colors and shapes presented
in the Hexagonal and Detail views allowed the domain expert to find a
specific hexagon very quickly (R1).
The task of analyzing compound similarity could be thoroughly
tested by means of different projections provided by ChemVA (R2).
Furthermore, during the two case studies it was possible to examine
these projections in terms of their trustworthiness, using the provided
correlation scores (R3), and to compare them by means of the Dif-
ference view (R2). These two features provided by ChemVA aided
the domain expert in the first case study in order to assess whether
the projections were trustworthy and thus hexagons were effectively
grouping similar compounds.
The evaluation also showed the usefulness of the 3D view to dis-
cover and analyze similar 3D structures among the selected compounds
Fig. 9: Illustration of the exploratory process in the P-glycoprotein dataset, displaying only a subset of interesting molecules in the Detail view
and selecting those with high logP values.
(R5). Examining the chemical determinants for bioactivity in both
case studies was straightforward by means of the molecular alignment
function provided by ChemVA, according to the domain expert. Every
subset of molecules could be quickly aligned on demand, in contrast to
other chemical software tools, where this task constitutes a strenuous
process and it is often restricted to molecules above a certain threshold
of structural similarity [16]. Moreover, structural patterns could be fur-
ther explored using the opacity filter and invert opacity option, which
allow highlighting the different parts of the compounds.
The coordination of the plots with the Table view was also found
useful by the domain experts (R4), offering fast access to summary
information in its column headers. The Table view proved to be effec-
tive for exploring a large dataset, such as P-glycoprotein, enabling the
search for rare feature values through filtering and hierarchical grouping
during the second case study. Other functionalities, such as showing
SMILES formulas for copying, the option for exporting 3D structures,
or searching compounds by SMILES formula, made ChemVA a flexible
tool, easily interoperable with other cheminformatics tools.
One limitation identified during the first case study is that new
compounds were not always projected near to structurally similar com-
pounds. This functionality performed consistently better on some
molecular representations than the others, as it can be seen in Figure 8.
This might be related to the fact that the dataset serotonin-dopamine
used in the experiment is small (118 compounds), thus the neural-based
parametric model trained for projecting new compounds is not able to
generalize well for every molecular representation. Another limitation
we identified is that not all compounds have available 3D structures,
which may limit the usage of the 3D view with some datasets.
ChemVA proved to be useful both as an exploration and visualization
tool, and it also helped the domain expert with the design and evaluation
of new compounds (R6) during the first case study. As discussed in
Section 6.2, ChemVA was also praised as a useful and innovative tool
by the domain experts during the external evaluation.
We also identified potential directions for future extensions of the
tool, accounting both for user experience and functionality. The exter-
nal domain experts suggested expanding the current functionality of the
tool by enabling the user to load and customize their own data. One of
the domain experts also suggested to enable adding new compounds by
drawing them in a sketcher. Other possible directions include providing
options for substructure search or to enhance navigation by providing
breadcrumbs and saving analytical snapshots.Lastly, it is worth noticing
that although our tool is domain-specific, ChemVA has been developed
by following techniques and strategies that could be applied to other
types of data, including non-chemical data. For instance, our newly
proposed Difference view could assist in the process of visually analyz-
ing the preservation of clusters and neighborhoods for most clustering
methods. Also, the analysis of trustworthiness of DR projections could
be applicable to any type of data undergoing a DR procedure. The idea
behind the 3D view, which allows for overlapping common molecular
substructures, could be applied to other graph-based data or even text.
8 CONCLUSIONS
In this paper, we presented ChemVA, a novel tool for visual analysis
of chemical compounds, which is especially focused on evaluating
molecular similarity for virtual screening. Our tool proposes a set of co-
ordinated views that support visual exploration and comparison of 2D
projections, which are obtained from applying dimensionality reduction
on different—and ideally, complementary—molecular representations.
Our case studies, conducted by a medicinal chemist, confirmed that
ChemVA addresses the functional requirements and provided appropri-
ate support for his analysis on two different datasets. The qualitative
evaluation conducted by three other external experts revealed the poten-
tial of our tool for its adoption in the domain, as well as the usefulness
of our newly proposed Difference view. The evaluation process allowed
us to identify potential extensions to ChemVA, which will steer our
future work on the tool.
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SUPPLEMENTARY MATERIAL
In this Supplementary Material, we provide the readers with detailed
information about data preprocessing performed for ChemVA and
computational times, as well as the results of the molecular docking
performed for the Case study. Although this document contains im-
portant information for reproducing our approach and the experiments
conducted during the evaluation of the tool, its contents are not crucial
for understanding the visualization concepts used in ChemVA, which
constitute the core of our proposal.
DATA PREPROCESSING
In this section we describe the computation of the vector-based molecu-
lar representations and the equations used for computing the correlation
scores. We also provide details on the parameterization of our DR
method, parametric models and molecular alignment back-end service.
The information presented in this section is relevant for reproducibility
purposes.
Vector-based Molecular Representations
In order to provide domain experts with diverse information about the
ligands in our datasets, we computed four different molecular represen-
tations, which we then used as sources of data for our 2-dimensional
projections. For each dataset, we computed radius 2 ECFPs and Day-
light fingerprints, both 1024 bits long, using the Chem and AllChem
packages of RDKit [36]. We also computed 0D, 1D, and 2D molecular
descriptors using Mordred [46], obtaining a total of 1613 descriptors.
We removed all descriptors that had more than 10%NaN values and
replaced all remaining NaN with a fixed value (maximum value per
descriptor), which yielded 1454 molecular descriptors. Finally, we used
a pretrained Mol2Vec model [23], which computed 300-dimensional
embeddings based on the SMILES formulas of the compounds in the
datasets. The computation of ECFPs, Daylight fingerprints and molecu-
lar descriptors took less than an hour, and it was performed in a 32-core
cluster with 12GB memory. This preprocessing stage was performed
offline, which means that it was done once and then the results were
stored for future use.
Features for Drug-Likeness
The features related to drug likeness are displayed in the Table view
and can be color encoded onto the Detail and Hexagonal views as well.
The values for such features were obtained using a publicly available
REST API by ChEMBL [14]. The collected values did not undergo
any further preprocessing steps.
t-SNE Projections and Parametric Models
We computed a t-SNE projection for each of the vector-based molecular
representations, for both of the datasets used in the case study. The
t-SNE projections were computed using the manifold class from Scikit-
Learn [52], and the parameters used were selected by grid search. The
tested perplexity values varied from 5 to 10% of the total amount of
compounds in the dataset. The same parameterization on each dataset
was used to fit t-SNE for each of the vector-based molecular represen-
tations. Fitting each t-SNE projection took around 20 minutes on a
32-core cluster with 12GB memory. A summary of the parameteriza-
tion used for t-SNE is provided in Table 1.
Table 1: Summary of the parameters used to fit the t-SNE projections
of each dataset.
Dataset P-glycoprotein Serotonin-Dopamine
Perplexity 45 5∼10
Maximum No. epochs 10000 10000
No. epochs without progress 500∼1000 1000
After fitting each t-SNE projection, we trained one parametric model
to learn each of such projections. The parametric models were built
using Keras and Tensorflow [8]. The parameterization of these models
is summarized in Tables 2 and 3. The computational time invested
on training these models was of approximately 30 minutes per model,
on a 32-core cluster with 12GB memory. Both the fitting of the t-
SNE projections and the training of the parametric models consisted of
offline tasks.
Correlation Scores for Measuring the Trustworthiness of
Projections
t-SNE applies two different distributions to map data points to a lower-
dimensional space in an effort to preserve neighborhoods according
to a specific optimization criterion. As a result, pairwise distances
among the compounds in the low-dimensional space could be distorted
with respect to distances in the high-dimensional space, and those
differences could mislead the domain expert during the virtual screening
process. For this reason, as a means to assess the trustworthiness of the
projections, we computed two different correlation scores for each of
the compounds.
The first score, namely r, was computed by calculating the cosine
distance of each compound k to the rest of the compounds in the high-
dimensional space and then measuring the Pearson correlation (see
Equation 1) among these distances and the ones in the low-dimensional
space. Pearson correlation has been previously used by Strickert et
al in MSR [69], which has also been applied to chemical compounds.
The second score, namely τ , was computed by generating two ranks
for each compound k, one in the origin space and another one in the
mapped space, which sort all the compounds according to the cosine
distance to k. Afterwards, the score was computed by comparing both
ranks using the Kendall rank correlation (see Equation 2).
Both correlation scores were computed for each compound individ-
ually, and once for each of the four vector-based molecular represen-
tations used in ChemVA, which yields four different views on which
the trustworthiness of each projection can be assessed. In addition, the
difference graph uses the Kendall rank correlation scores as the default
encoding. These scores were computed using tools in the Python Data
Science suite SciPy [28] and Scikit-Learn [52].
r =
n(∑xy)− (∑x)(∑y)√[
n∑x2− (∑x)2
][
n∑y2− (∑y)2
] (1)
τ =
nconcordants−ndiscordants
n(n−1)/2 (2)
Molecular Alignment and 3D Conformations
ChemVA supports a 3D view, which allows the user to conduct a de-
tailed analysis of the molecular structures under study, and to visually
explore common geometrical patterns among compounds. The 3D
conformations of compounds were retrieved from PubChem [30] and
computed using OpenBabel [51]. The computed 3D conformations
were obtained using Ghemical force field energy minimization, force
field cleanup (500 cycles) and slow rotor search.The computation of
these 3D conformations consisted of an offline task. It took approxi-
mately between 2 and 20 minutes for each compound, depending on
the complexity of its molecular structure, and it was performed on a
32-core cluster with 12GB memory.
The molecular alignment function involves two steps. The first step
consists of finding the maximum common substructure (MCS) among
the selected compounds, which is achieved using RDKit [36]. The
second step consists of aligning all the selected molecules with respect
to the found MCS, and it is done using the obfit function provided
by OpenBabel [51]. The molecular alignment task is performed on
demand: it is an online task, which means that it is performed upon
the selection of a set of compounds in the Detail view in our back-end
servers. The response time of this web service is of approximately one
second, tested on random selections from 5 to 30 compounds.
Adding New Compounds
The addition of new compounds to the Detail view is an online task,
performed on demand in our back-end servers. The parametric models
Table 2: Summary of the parameters used to build and train the four parametric models for P-glycoprotein dataset.
Parameters ECFPs Daylight fps Molecular descriptors Molecular embeddings
# Nodes per hidden layer 100 / 10 / 2 100 / 10 / 2 200 / 20 / 2 100 / 10 / 2
Activation fn relu relu relu relu
Dropout coefficients 0.25 / 0.15 / 0.1 0.25 / 0.15 / 0.1 0.25 / 0.15 / 0.1 0.25 / 0.15 / 0.1
Early stopping patience 70 130 120 50
Early stopping delta 0.005 0.005 0.005 0.005
Learning rate (Adam opt) 0.0001 0.0001 0.0001 0.0001
Table 3: Summary of the parameters used to build and train the four parametric models for serotonin-dopamine dataset.
Parameters ECFPs Daylight fps Molecular descriptors Molecular embeddings
# Nodes per hidden layer 50 / 10 / 2 50 / 10 / 2 200 / 50 / 2 50 / 10 / 2
Activation fn relu relu tanh sigmoid
Dropout coefficients 0.25 / 0.15 / 0.1 0.25 / 0.15 / 0.1 0.25 / 0.15 / 0.1 0.25 / 0.15 / 0.1
Early stopping patience 70 70 100 70
Early stopping delta 0.005 0.005 0.005 0.005
Learning rate (Adam opt) 0.0001 0.0001 0.0001 0.0001
are previously loaded, which reduces significantly the response time:
approximately four seconds per compound.
CASE STUDY 1 - MOLECULAR DOCKING
This section provides details on the two datasets used in the case studies,
as well as on the results of the molecular docking study performed by
the domain expert in the context of our case study 1 (see Section 6 of
the paper).
Dataset Selection and Preprocessing
The two datasets used in the case studies, namely serotonin-dopamine45
and P-glycoprotein6, were built upon two different datasets retrieved
from ChEMBL [14]. We performed a preliminary selection step of
the SMILES formulas on each of the datasets, keeping only those
compounds that could be loaded using RDKit [36]. Details on the
amount of compounds belonging to each class are provided in Tables 4
and 5. The compounds were labeled according to their experimentally
measured IC50 bioactivity value towards the targets under study.
Table 4: Details on the composition per class of the P-glycoprotein
dataset.
Class P-glycoprotein
# compounds
per class
Active 42
Moderately active 178
Inactive 673
Total 893
Table 5: Details on the composition per class of the serotonin-dopamine
dataset.
Class Serotonin 1a Dopamine D2
# compounds
per class
Active 14 5
Moderately active 42 28
Inactive 62 85
Total 118 118
Preparation of Receptor Structures
The structure of human 5HT1A receptor was constructed using ho-
mology modeling using the I-TASSER web server using default set-
4https://www.ebi.ac.uk/chembl/target report card/CHEMBL214/
5https://www.ebi.ac.uk/chembl/target report card/CHEMBL217/
6https://www.ebi.ac.uk/chembl/target report card/CHEMBL4302/
tings [88]. The model was constructed using homologous 5HT re-
ceptors and monoamine receptors with resolved structures. Model 1
was selected for the docking study with a TM-score of 0.52 ± 0.15,
indicating a well-predicted fold [92]. The model was aligned to the
homologous structure of 5HT1B (PDB ID 4IAR [79]) and showed a
nearly perfect overlap. The structure of the dopamine D2 receptor was
downloaded from PDB [4] (PDB ID 6CM4 [81]). Hydrogens, ions,
and waters were removed using PyMOL [64]. The protonation state of
titratable groups, as well as the orientation of Asn, Gln, and His groups,
were corrected by the H++ web server using pH 7.5 [1].
Preparation of Ligand Structures
Based on the three structures selected in ChemVA, five new ligand
structures were designed using Avogadro [18]. Molecular docking
aimed to compare binding energies and binding modes of the three
dataset structures and those of the five designed structures. The molecu-
lar docking was done using Autodock Vina [75]. Autodock atom types
and Gasteiger charges were added to the two receptors and the ligands
using MGLTools [47, 63]. The docking grid was selected to be a 30
x 30 x 30 A˚ cube. For the 5HT1A receptor, the cube was centered on
the bound ligand in the aligned structure of 5HT1B. For the dopamine
D2 receptor, the cube was centered on the bound ligand in the receptor
structure.
Results and Discussion
All of the seven structures successfully bound to the binding pockets
of the two receptors, suggesting a plausible binding mode was found.
Three of the five designed structures showed a lower value binding
energy, indicating a stronger binding. The binding energies of the best
binding modes are shown in Table 6, and the SMILES formulas for
each of the designed compounds are provided in Table 7.
In this comparison, designed compounds 2, 4, and 5 exhibited higher
predicted affinities to both receptors. These predicted results do not
necessarily mean higher inhibitory activity, given that such bioactivity
can be influenced by other factors such as flexibility of the receptor
proteins.
In addition, we provide supplementary files comprising the results
from the I-TASSER web server and the input files and results from the
Autodock Vina procedure.
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Table 6: Predicted binding affinities towards the serotonin 5HT1A
receptor (5HT1A) and dopamine D2 receptor (dopD2) of both selected
dataset compounds and designed compounds, measured in kcal/mol.
Rows in bold show the compounds exhibiting the highest predicted
affinities to both receptors.
Compound Affinity to 5HT1A Affinity to dopD2
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